PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.080
+0.150 (16.13%)
At close: Apr 28, 2026, 4:00 PM EDT
1.070
-0.010 (-0.93%)
After-hours: Apr 28, 2026, 7:59 PM EDT
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,437,313
Market Cap
60.28M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| Xilio Therapeutics | 76 |
| MiNK Therapeutics | 23 |
| Entera Bio | 22 |
| Atossa Therapeutics | 16 |
| Instil Bio | 14 |
| Nutriband | 13 |
| Kezar Life Sciences | 9 |
PDSB News
- 13 days ago - PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial - GlobeNewsWire
- 4 weeks ago - PDS Biotechnology Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - GlobeNewsWire
- 5 weeks ago - PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - GlobeNewsWire
- 2 months ago - PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - GlobeNewsWire
- 3 months ago - PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - GlobeNewsWire
- 3 months ago - PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - GlobeNewsWire
- 3 months ago - PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint - GlobeNewsWire